Demographic, Clinical, and Laboratory Characteristics and Outcomes of Patients Who Ever Received Etravirine and/or Darunavir – Multi-country Data Abstraction
Overview
Country:
Cameroon; Eswatini; Kenya; Lesotho; Nigeria; Rwanda; Uganda; Zambia; Zimbabwe
Subject Matter:
Innovative Technologies; Pediatric and Adolescent Testing, Care, and Treatment
This multi-country study, funded by Johnson and Johnson, will describe the demographic, clinical, and laboratory profiles of patients receiving donated Etravirine and/or Darunavir. The study also aims to identify the dynamics in HIV drug resistance mutations among patients who fail treatment on new regimens and to describe the profiles of young adults who transition out of the program at 12 months after their transition.
Data Collection Period: 08/2018 – 12/2022
Publications and Presentations:
- Findings presented at the 23rd International AIDS Conference, July 2020: “HIV-infected treatment-experienced children and adolescents from Sub-Saharan Africa: Clinical outcomes on third-line antiretroviral treatment in the New Horizons drug donation program“
- Findings presented at the 12th International Workshop on HIV & Pediatrics, November 2020: “HIV-infected treatment-experienced children and adolescents from Sub-Saharan Africa: Clinical outcomes on third-line antiretroviral treatment in the New Horizons drug donation program”
- Findings presented at the 13th International Workshop on HIV Pediatrics, July 2021: “HIV Drug Resistance Patterns Among Highly Treatment-Experienced Children, Adolescents and Young Adults in Sub-Saharan Africa”
